UBS Initiates Coverage On Mineralys Therapeutics with Neutral Rating, Announces Price Target of $29
UBS analyst Alice Nettleton initiates coverage on Mineralys Therapeutics (NASDAQ:MLYS) with a Neutral rating and announces Price Target of $29.
Stocks · News reference
Mineralys Therapeutics To Present Five Abstracts At American Heart Association Hypertension Scientific Sessions 2026,
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
HC Wainwright & Co. Reiterates Buy on Mineralys Therapeutics, Maintains $56 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and maintains $56 price target.
Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026
Mineralys Therapeutics presented new clinical trial data for lorundrostat, its investigational aldosterone synthase inhibitor for treating difficult-to-treat hypertension. The Launch-HTN trial showed 46% of participants achieved AHA/ACC guideline systolic blood pressure targets (<130 mmHg) at 12 weeks, with over two-thirds achieving ≥10 mmHg reduction. The Explore-OSA trial demonstrated clinically meaningful morning blood pressure reductions in obstructive sleep apnea patients with no adverse effects on sleep apnea indices.
Mineralys Therapeutics Reports New Data Of Analysis From Its Pivotal Phase 3 Launch-HTN Study